Iron-chelation therapy: An update

Hematology Journal

Volumn 5, Issue 4, 2004, Pages 287-292

  Franchini, Massimo ^a   Veneri, Dino ^b  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Desferrioxamine; Iron overload; Oral iron chelators; Therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE MESYLATE; FERRITIN; IRON; IRON CHELATING AGENT; PLACEBO;

AGRANULOCYTOSIS; ARTHROPATHY; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTINUOUS INFUSION; DEATH; DRUG ABSORPTION; DRUG ERUPTION; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENTIATION; DRUG WITHDRAWAL; GASTROINTESTINAL DISEASE; HUMAN; INFUSION PUMP; IRON CHELATION; IRON OVERLOAD; LIFE EXPECTANCY; LIVER DYSFUNCTION; LIVER FIBROSIS; MOTIVATION; NEUTROPENIA; PATIENT COMPLIANCE; REVIEW; THALASSEMIA MAJOR; TREATMENT OUTCOME;

BLOOD TRANSFUSION; CLINICAL TRIALS; HUMANS; IRON; IRON CHELATING AGENTS;

EID: 4544237005     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200407     Document Type: Review

References (41)

1. Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR et al. Survival and disease complications in thalassemia major. Ann NY Acad Sci 1998; 850: 227-231.
2. Olivieri NF. The β-thalassemias. N Engl J Med 1999; 341: 99-109.
3. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol 1996; 95: 26-36.
4. Giardina PJ, Grady RW. Chelation therapy in β-thalassemia: the benefits and limitations of desferrioxamine. Semin Hematol 1995; 32: 304-312.
5. Franchini M, Gandini G, Aprili G. Advances in iron-chelating therapy. Haematologica 2000; 85: 1122-1125.
6. Porter JB. Practical management of iron overload. Br J Haematol 2001; 115: 239-252.
7. Olivieri NF, Brittenham GM. Iron-chelation therapy and the treatment of thalassemia. Blood 1997; 89: 739-761.
8. Borgna-Pignatti C, Cohen A. An alternative method of subcutaneous deferoxamine administration. Blood 1995; 86 (Suppl.): 483 (abstract).
9. Borgna-Pignatti C, Franchini M, Gandini G, Vassanelli A, de Gironcoli M, Aprili G. Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematological diseases and iron overload. Haematologica 1998; 83 788-790.
10. Di Gregorio F, Romeo MA, Pizzarelli G, Aiello G, Russo G. An alternative to continuous subcutaneous infusion of desferrioxamine in thalassemic patients. Br J Haematol 1997; 98: 601-602.
11. Porter JB, Srichairatanakool S, Nathan DG, Schinkel H, Gee B, Olivieri NF. Relative efficacy of subcutaneous infusion and bolus injections of deferoxamine in the removal of non-transferrin-bound iron (NTBI). Blood 1998; 92 (Suppl.) 668 (abstract).
12. Franchini M, Gandini G, de Gironcoli M, Vassanelli A, Borgna-Pignatti C, Aprili G. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. Blood 2000; 95: 2776-2779.
13. Franchini M, Gandini G, Veneri D, Aprili G. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload: an update. Blood 2004; 103:747-748.
14. Liu DY, Liu ZD, Hider RC. Oral iron chelators - development and application. Best Pract Res Clin Haematol 2002; 15: 369-384.
15. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003; 102: 17-24.
16. Addis A, Lochstein R, Koren G, Einarson TR. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1). Eur J Clin Pharmacol 1999; 55: 1-6.
17. Bartlett AN, Hoffbrand AV, Kontoghiorghes GJ. Long-term trial with the oral iron chelator 1,2-dymethyl-3-hydroxypyrid-4-one (L1). 2. Clinical observations. Br J Haematol 1990; 76: 301-304.
18. Töndury P, Kontoghiorghes GJ, Ridolfi-Lüthy A, Hirt A, Hoffbrand AV, Lottenbach AM et al. L1 (1,2-dymethyl-3-hydroxypyrid-4-one) for oral iron chelation in patients with beta-thalassemia major. Br J Haematol 1990; 76: 550-553.
19. Agarwal MB, Gupte SS, Viswanathan C, Vasandani D, Ramanathan J, Desai N et al. Long-term assessment of efficacy and safety of L1, an oral iron chelator, transfusion dependent thalassemia: Indian trial. Br J Haematol 1992; 82:460-466.
20. Al-Refaie FN, Hershko C, Hoffbrand AV. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. Br J Haematol 1995; 91: 224-229.
21. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron LG et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995; 332: 918-922.
22. Kersten MJ, Lange R, Smeets MEP, Vreugdenhil G, Roozendaal KJ, Lameijer W et al. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. Ann Haematol 1996; 73: 247-252.
23. Hoffbrand AV, Al-Refaie F, Davis B. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998; 91: 295-300.
24. Mazza P, Amurri B, Lazzari G, Masi C, Palazzo G, Spartera MA et al. Oral iron-chelating therapy. A single center interim report on deferiprone (L1) in thalassemia. Haematologica 1998; 83: 496-501.
25. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, McClelland RA et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998; 339:417-423.
26. Rombos Y, Tzanetea R, Konstantopoulos K, Simitzis S, Zervas C, Kyriaki P et al. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1). Haematologica 2000; 85: 115-117.
27. Del Vecchio GC, Crollo E, Schettini F, Schettini F, Fischer R, De Mattia D. Factors influencing effectiveness of deferiprone in a thalassemia major clinical setting. Acta Haematol 2000; 104: 99-102.
28. Taher A, Sheik-Taha M, Koussa S, Inati A, Neeman R, Mourad F. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients. Eur J Haematol 2001; 67: 30-34.
29. Maggio A, D'Amico G, Morabito A, Capra M, Ciaccio C, Cianciulli P et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis 2002; 28: 196-208.
30. Ceci A, Baiardi P, Felisi M. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002; 118: 330-336.
31. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102: 1583-1587.
32. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennel DJ. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002; 360: 516-520.
33. Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003; 88: 489-496.
34. Grady RW, Giardina PJ. Iron chelation with oral deferiprone in patients with thalassemia. N Engl J Med 1998; 339: 1712-1713, (letter).
35. Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002; 100: 1566-1569.
36. Wonke B, Wright C, Hoffbrand AV. Combine therapy with deferiprone and desferrioxamine. Br J Haematol 1998; 103: 361-364.
37. Mourad FH, Hoffbrand AV, Sheik-Taha M, Koussa S. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron over-loaded thalassemia patients. Br J Haematol 2003; 121: 187-189.
38. Aydinok Y, Nisli G, Kavakli K. Sequential use of deferiprone and desferrioxamine in primary school children with thalassemia major in Turkey. Acta Haematol 1999; 102: 17-21.
39. Hershko C, Konijn AM, Nick HP, Breuer V, Cabantchik ZI, Link G. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood 2001; 97: 1115-1122.
40. Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Séchaud R. Safety, tolerability and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia. J Clin Pharmacol 2003; 43: 565-572.
41. Nisbet-Brown E, Olivieri NF, Giardina PJ, Grady RW, Neufeld EJ, Sechaud R et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003; 361: 1597-1602.